Partners

Principal Investigator


Prof. Alessio Fasano (M) is Director of EBRIS, Vice Chair of Basic, Translational, and Clinical Research and Division Chief of Paediatric Gastroenterology and Nutrition at the Mass General Hospital for Children in Boston. He also serves as the Director of the Mucosal Immunology and Biology Research Centre and Director of the Centre for Celiac Research at the same Institution. In recent years, Dr. Fasano’s research has focused on the pathophysiology and role of intercellular tight junctions and gut microbiome in the pathogenesis of autoimmune and inflammatory diseases, with special emphasis on celiac disease and type 1 diabetes. Dr. Fasano has published more than 280 peer-reviewed papers and has filed more than 160 patent applications, many of which have been granted. Dr. Fasano has been awarded several prizes for his translational science, including the 2012 Shwachman Award, the 2012 Magister Insignins Award, the 2013 Linus Pauling Award and the 2014 Paul Harris Fellow Award. Dr Fasano identified in 2000 for the first time a protein that modulates the permeability of tight junctions between cells of the wall of the digestive tract, zonulin, that revolutionized our ability to understand the gut and permeability and how this impacts a wide range of health conditions from cancer to autoimmune disease to inflammation and food sensitivities.
  • European Biomedical Research Institute Salerno (EBRIS)

    Salerno, Italy

    www.ebris.eu

    Person in charge of the project: Prof. Alessio Fasano

  • Nutricia Research B.V. (NUT)

    Department: EU Projects - Uppsalalaan 12, Utracht
3584 CT, Netherlands

    www.nutriciaresearch.com

    Person in charge of the project: Dr. Anita Hartog

  • Medinok S.p.A. (MED)

    Volla –Napoli, Italy

    medinok.it

    Person in charge of the project: Mrs Martina Iandoli

  • Bio-Modeling Systems (BM Systems or BMS)

    Paris,France

    http://www.bmsystems.net/

    Person in charge of the project: Dr. Manuel Gea

  • Euformatics Oy (EUF)

    Espoo, Finland

    www.euformatics.com

    Person in charge of the project: Dr. Christophe Roos

  • Theoreo SRL (THE)

    Montecorvino Pugliano, Italy

    http://www.theoreosrl.com/

    Person in charge of the project: prof. Jacopo Troisi

  • National University of Ireland Galway (NUIG)
    Irish Centre for Autism & Neurodevelopmental Research (ICAN)
    Department: School of Psychology

    GALWAY, Ireland

    http://www.nuigalway.ie/

    Person in charge of the project: Dr. Geraldine Leader

  • Azienda Sanitaria Locale Salerno (ASL)

    Salerno, Italy

    http://www.aslsalerno.it/

    Person in charge of the project: Mrs. Laura Russo

  • The General Hospital Corporation
    Mucosal Immunology and Biology Research Centre and Lurie Centre
    Massachusetts General Hospital for Children (MGHfC or MGH)

    Charlestown , MA, United States

    www.partners.org

    Person in charge of the project: Prof. Alan Walker

  • National Council of Research - Institute of Biomedical Technologies (CNR-ITB)

    Segrate, Italy

    www.itb.cnr.it

    Person in charge of the project: Dr. Luciano Milanesi

  • French National Institute for Agricultural Research (INRA)
    Department: MICALIS & MetaGenoPolis

    PARIS CEDEX 07, France

    www.inra.fr

    Person in charge of the project: Dr. Silvye Rabot

  • Institut National de la Santé et de la Recherche Médicale (INSERM or Inserm)
    Department: UMR1239

    Paris, France

    www.inserm.fr

    Person in charge of the project: Mr. Anthony Delsine

  • Universiteit Utrecht (UU) - Utrecht Institute for Pharmaceutical Sciences

    Utrecht, Netherlands

    www.uu.nl

    Person in charge of the project: Prof. Aletta Kraneveld

  • Tampere University (UTA)

    Tampere, Finland

    www.tuni.fi

    Person in charge of the project: Dr. Reija Autio

  • Imperial College of Science, Technology and Medicine (ICL) Department of Biomolecular Medicine

    London, UK

    http://www.imperial.ac.uk/

    Person in charge of the project: Prof. Jeremy Nicholson

  • Johns Hopkins University (JHU) - Department of Mental Health

    Baltimore, Maryland, United States

    www.jhu.edu

    Person in charge of the project: Dr. Daniele Fallin

European Biomedical Research Institute Salerno (EBRIS)

The organization

the EBRIS Foundation’s mission is to serve as a unique multidisciplinary research hub focused on using cutting edge technologies to understand the molecular basis of human diseases in order to translate basic discoveries made in the laboratory into novel therapeutic and preventive interventions, new models of human disease, pioneering therapies, and drug delivery systems that can benefit patients with various diseases. The objective of the EBRIS Foundation is network with other European research groups to create a top-level research network through the development of projects focused on the interplay between host and environment. Clinical models such as celiac disease, type 1 diabetes, autism and schizophrenia are thoroughly investigated to determine how environmental factors, especially during the first years of life, influence the microbiome, some specific metabolic patterns, and the mechanisms that govern the switch between tolerance and immunity in autoimmune diseases. The EBRIS Foundation has already established a network of European research institutes starting from pre-existing interactions coordinated by the Massachusetts General Hospital of the Harvard Medical School. In addition, the Foundation can rely on a local and national network of medical institutions, universities and health companies.

Role in the Project

EBRIS will lead WP9 (management) and WP6 (clinical trials). EBRIS will also be in charge of some specific aspects of the research plan, including the evaluation of gut permeability by serum screening tests and molecular analysis of the results obtained in WP3 (immune function analysis) and the interpretation of the multi-omic analyses in WP4 (multiomic analysis). EBRIS will also support WP1 (mechanistic pathway hypotheses), WP2 (genome, epigenome and microbiome), WP5 (pre-clinical trials), WP7 (dissemination) and WP8 (exploitation). EBRIS will be in charge of organizing the Global GEMMA Summit.

Nutricia Research B.V. (NUT)

The organization

Nutricia is a specialized healthcare division of the food company Danone, focused exclusively on research- based scientifically-proven nutrition, to support early life development and to meet the needs of patients and individuals for whom a normal diet is not sufficient or possible. Nutricia has facilities in 34 countries and our products are available for patients in 74 countries. Nutricia Research is the global R&D organisation behind the Early Life Nutrition and Advanced Medical Nutrition divisions of Danone. Our goal is to bring health through food to as many people as possible. Nutricia Research is the research and innovation centre behind many well-known brands for infant formula, cereals and wet foods. We have products for people with specific nutritional needs, such as those with muscle loss, malnutrition, allergies and Alzheimer’s disease.

Role in the Project

NUT will lead WP8 (exploitation) in developing the exploitation strategy and plan and creating the business case and developing the business plan. NUT will provide nutritional formulations for WP5 (pre-clinical trials) and WP6 (clinical trials). NUT will also support WP1 (mechanistic pathway hypotheses), WP3 (metabolic and immune function profiles) and WP7 (dissemination).

Medinok S.p.A. (MED)

The organization

Medinok is an SME founded more than 25 years ago as subsidiary of Ericsson Telecommunications. In 2010, Medinok extended its activities worldwide in the ICT areas, becoming a preferred partner of Alcatel- Lucent N.V. for telecommunication, information and security systems. Medinok has developed its software division, focusing on Big Data technologies and services for the healthcare sector. Medinok has a turnover of 20M Euros and employs 250 experts in Italy. Today, Medinok provides the following products and services to the healthcare industry:
  • transmission, storage and analysis of large clinical datasets
  • basic statistical methods
  • measurements of outcome in clinical trials
  • clinical study design and research protocols
  • data transmission equipment
  • software design
  • software engineering
  • network engineering

Role in the Project

MED will lead WP8 (exploitation) and will support WP4 (multi-omic analysis) identifying meaningful correlations between multi-omnics data and clinical data related to enrolled patients. MED will also contribute to WP1 (mechanistic pathway hypotheses), WP6 (clinical trials), WP7 (dissemination).

Bio-Modeling Systems (BM Systems or BMS)

The organization

BMS is an independent Private Company incorporated in 2004, profitable since 2006 and 100% owned by its founders (no external investors). BMS is the first Mechanisms-Based Medicine company that discovers novel diagnostic, therapeutic & prevention solutions. The company favours long term strategic R&D and business collaborations and has more than 100 partners’ professionals working on BMS’ related R&D programs. BMS’ original dual business model generates revenues through contractual R&D programs & patented novel therapeutic & prevention solutions via collaborative R&D partnerships programs. The company is strictly focused on discovery; the validation phases and the development of its patented discoveries are implemented outside the company by selected partners.

Role in the Project

BMS will lead WP1 (mechanistic pathway hypothesis) and support WP2 (microbiome, genome and epigenome profiling) and WP4 (multi-omics analysis). BMS will also support WP7 (dissemination) and WP8 (exploitation).

Euformatics Oy (EUF)

The organization

Euformatics is a research-performing SME focusing on the quality management and analysis of genomic and transcriptomic next generation sequence data. Euformatics develops both cloud-based and local enterprise solutions (omnomicsQ, omnomicsNGS) combining a database platform with computational analysis functionality. omnomicsNGS offers a comprehensive configurable genome variant interpretation environment for the needs of clinical research and genetic counselling laboratories, in oncology as well as for rare genetic diseases. omnomicsQ implements NGS bioinformatics quality control best practices and allows labs to validate tests and to follow changes in NGS quality over time, by chemistry or by instrument. It provides tools for benchmarking internally and externally to facilitate process optimisation. It provides long- term storage of quality policies and of quality reports. Euformatics is constantly innovating as a consequence of its tight collaborations with academic and clinical partners. Since 2015 Euformatics operates the European Molecular Genetics Quality Network (EMQN) and UK-NEQAS external quality assessment (proficiency testing) schemes based on omnomicsQ and its omnomicsNGS software has received CE- marking as a medical device, class 1

Role in the Project

EUF will lead WP2 (genome, epigenome and microbiome). EUF will provide a software infrastructure (omnomicsQ) for managing NGS quality metrics and another software infrastructure (omnomicsNGS) for the analysis and the interpretation of the genomic variants of the patient material as well as for the comparison of the variants from the different patient cohorts. The software infrastructure will be developed further to include epigenomics & transcriptomics data from DNAm measurements as/if required by other parts of the project. EUF will contribute to WP1 (mechanistic pathway hypotheses) and WP4 (multi-omic analysis). Finally EUF will support WP7 (dissemination) and WP8 (exploitation).

Theoreo SRL (THE)

The organization

Theoreo Srl is an innovative SME, founded as a spin-off of the Department of Medicine and Surgery of the University of Salerno. The main scope of activity is represented by diagnostic techniques based on metabolomics and classification models and machine learning. The company has already established bilateral agreements and research protocols with Italian Universities and Public Research Centres. It has two patent-pending inventions and has also developed and commercialized, all over Italy, a kit for metabolome extraction, purification and derivatization from several biologic tissues called MetaboPrep

Role in the Project

THE will support WP1 (mechanistic pathway hypotheses) and WP3 (metabolome). THE is in charge of the short chain fatty acid analysis via LCMS/GSMS. THE will also support WP7 (dissemination) and WP8 (exploitation).

National University of Ireland Galway (NUIG)
Irish Centre for Autism & Neurodevelopmental Research (ICAN)
Department: School of Psychology

The organization

National University of Ireland Galway, (NUIG), is world-renowned as an expert research-led University. With emphasise on inter-disciplinary research programmes, and collaborations with industry partners in areas of strategic importance at regional, national and international level. NUIG is ranked among the top 1% of Universities in the world. The University is ranked 148 in the 2017 QS World Rankings and has also been awarded the full five QS stars for Excellence. NUIG has created a reputation for research excellence across five cross-disciplinary research themes: Applied Social Sciences and Public Policy; Biomedical Science and Engineering; Environment, Marine and Energy; Humanities in Context, including Digital Humanities; Informatics, Data analysis, Physical and Computational Sciences. In 2017 the annual direct research income of NUIG was €65m. NUIG has attracted over 50 Million Euro EU funding with notable successes in the Capacities, Cooperation, Ideas and People programmes, leading to over 1,500 indexed publications and more than 22,000 annual citations. In 2013, NUIG was awarded the HR Excellence in Research Logo by the European Commission in recognition of their commitment in implementing the principles of European Charter & Code for Researchers. The Irish Centre for Autism and Neurodevelopmental Research (ICAN) is a Centre of Excellence, dedicated to ensuring improvements for all individuals with Autism Spectrum Disorder (ASD) through education, training, research and service provision. Our mission is to generate and disseminate empirically validated knowledge which will shape best practice in the areas of policy, education and intervention. ICAN is made up of 4 Principle Investigators, 8 Post-Doctoral Fellows and 12 PhD students. Staff and students conduct research into the study of ASD across the lifespan and have a proven track record in intervention research especially in the field of Applied Behaviour Analysis. Advanced Glycoscience Research Cluster (AGRC) at NUIG was established with the objective of understanding the role of glycosylation in host-microbial interactions within the gastro-intestine. Within the AGRC, custom lectin, neoglycoconjugate, glycan and mucin glyco arrays have been developed and undergo continual evolution to permit high-throughput (HTP) screening and glycomic profiling across a number of biological fields, including the development of novel glyco-diagnostic signatures for a range of diseases, infections (including stimuli exposure and host response) and biological interaction. In parallel, recognition molecule evolution to develop glycan specific recognition molecules (protein and nucleic acid based) to improve specificity and discrimination of individual glycan epitopes is applied. This approach is leading to new discoveries in the field of disease diagnostics and glycan triggered host response, allowing changes across tissues and single cells during disease stages to be monitored, leading to novel disease biomarkers and information led life style management for improved health state.

Role in the Project

At NUI Galway ICAN will lead patient recruitment in Ireland in WP6 (clinical trials). ICAN will also support WP4 (multi-omics analysis validation), WP7 (dissemination) and WP8 (exploitation). ICAN will perform all psychological and behavioural assessments. AGRC will contribute glycomic aspects and insights to in WP1, providing glycomic analysis and immune profiling in WP3 and aspects of validation in WP4.

Azienda Sanitaria Locale Salerno (ASL)

The organization

ASL is a public company that coordinates 14 hospitals and a network of primary care districts for multi- specialist care. This network is coordinated with other medical institutions such as the University of Salerno Medical Hospital, the University of Naples Medical School “Federico II”, the Autism Unit of the Second University of Naples Medical Campus and the Fatebenefratelli Hospital in Naples. Within this network of health services clinics and centers, there are organized specific clinics for the care of patients suffering from ASD.

Role in the Project

ASL will lead patient recruitment in WP6 in Italy (clinical trials). ASL will perform all psychological and behavioural assessments. ASL will also support WP4 (multi-omics analysis validation), WP7 (dissemination) and WP8 (exploitation).

The General Hospital Corporation
Mucosal Immunology and Biology Research Centre and Lurie Centre
Massachusetts General Hospital for Children (MGHfC or MGH)

The organization

Located in the historic Charlestown Navy Yard, the Mucosal Immunology and Biology Research Centre (MIBRC) houses seven principal investigators. Supported by the staff and facilities of Massachusetts General Hospital and Harvard Medical School, MIBRC scientists conduct basic research in mucosal immunology topics ranging from Salmonella food poisoning to intestinal inflammatory diseases such as celiac disease and IBD. The centre is particularly focused on the impact of the gut microbiome on immune tolerance/immune response balance. The Lurie Centre is a multidisciplinary program designed to evaluate and treat children, adolescents and adults with a wide variety of conditions including autism and autism spectrum disorders, Asperger syndrome and developmental delays. It is the clinical arm of the Lurie Centre for Autism, which also has research, advocacy and training programs.

Role in the Project

MGH (MIBRC) will provide expertise in mucosal biology and immunology to support the proposed immunological and molecular biology components of WP3 (metabolic and immune function profiles). MGH (Lurie centre) investigators will be in charge of recruiting infants at risk of ASD in the USA and provide the proper clinical and regulatory support for the execution of the observational trial in WP6 (clinical trials). MGH will also support WP4 (multi-omics analysis validation), WP7 (dissemination) and WP8 (exploitation)

National Council of Research - Institute of Biomedical Technologies (CNR-ITB)

The organization

CNR-ITB is the largest institute of its kind in Italy and was established to pioneer new types of cross- disciplinary biomedical research by bringing biology, engineering, medicine, and the basic sciences together. This is achieved by means of collaborations between industry and basic scientists and clinicians from a broad range of disciplines. One of the most important aims of its research mission is translating fundamental discoveries into new technologies. The core research overview and the major focuses of the institute are: cancer & stem cell research, epidemiology, neurodegenerative diseases, neurodevelopmental diseases and immunology combined with the development of high-throughput bioscience research such as GWAs, proteomic-based technologies, genomics, Single Cell Analysis and bioinformatics.

Role in the Project

CNR-ITB will support WP1 (mechanistic pathway hypotheses) and WP2 (genome, epigenome and microbiome). CNR-ITB will support WP4 (multi-omics analysis) to validate the multi-omics platform and the potential biomarkers identified through the mechanistic integration of multi-omics data with environmental information, as well as support the project creating the consortium data repository built on generalist omics data storage and on the more specific ASD-specific omics repositories. CNR-ITB will also support WP7 (dissemination) and WP8 (exploitation).

French National Institute for Agricultural Research (INRA)
Department: MICALIS & MetaGenoPolis

The organization

INRA was created in 1946 and is currently Europe’s top agricultural research institute and the world number 2 centre for the agricultural sciences. INRA focuses on 3 highly interconnected topics: agriculture, environment, and nutrition. It counts approximately 8000 full time staff (50 % are women), and its research teams are supported by numerous experimental facilities. INRA is also strongly involved in innovation transfer to the private sector, through 2 subsidiary companies, i.e. Agri-Obtentions and INRA Transfer. In the field of nutrition, INRA has been carrying out researches into the gut microbiota for more than 50 years and ranks today among the most cited institutions in human gut metagenomics. In this proposal, INRA is represented by the Micalis Institute (UMR1319) and by MetaGenoPolis (US1367). Both laboratories are located in the INRA Research Centre “Ile-de-France Jouy-en-Josas”, close to Paris. The Micalis Institute (Food and Gut Microbiology for Human Health) gathers more than 300 research staff in food and gut microbiology, and MetaGenoPolis (MGP) offers expertise and houses equipment dedicated to high throughput metagenomics.

Role in the Project

INRA will lead WP2 (microbiome, genome and epigenome). Within this WP, INRA will be in charge of analysing the genomic and transcriptomic profiles of the host microbiota. INRA will also participate to WP5 (pre-clinical trials), contributing to mechanistic and interventional studies with gut microbiota-controlled models. INRA will also be involved in WP1 (mechanistic pathway hypotheses), WP7 (dissemination), and WP8 (exploitation).

Institut National de la Santé et de la Recherche Médicale (INSERM or Inserm)
Department: UMR1239

The organization

Inserm, created in 1964, is the only French national research institute entirely dedicated to Medical Research from basic to applied science, from the bench to the patient’s bedside. It has made many critical contributions to science, and among them, two were awarded a Nobel prize (Dausset J, 1980 and Barré- Sinoussi F, 2008). Inserm is the leading European academic biomedical research institution, and with nearly 12,000 publications a year; is second in the world only to the National Institutes of Health (NIH). According to the 2016 ranking by Thomson-Reuters, Inserm is also the world’s 9th most innovative public research organization. In this proposal Inserm is represented by the Inserm UMR1239 “Neuroendocrine and neuronal differentiation and communication” Laboratory located in CURIB (Centre Universitaire de Recherche et d’Innovation en Biologie) – in the Science campus of Rouen University of Normandy in Mont St Aignan. The CURIB is a modern research institute moreed in 2017 and is equipped with the state of the art research infrastructures including the imaging and proteomic platforms and animal facility. The scientific coordinator for Inserm will be Pr. S. Fetissov, a team leader in Inserm UMR1239.

Role in the Project

INSERM will support WP3 (microbiome, genome and epigenome) with proteomic analysis. INSERM will also contribute to WP1 (mechanistic pathway hypotheses), WP6 (dissemination) and WP7 (exploitation)

Universiteit Utrecht (UU) - Utrecht Institute for Pharmaceutical Sciences

The organization

The Division of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, has excellent and longstanding research tradition in the area of immune-, neuroimmuno- and psychopharmacology in relation to chronic inflammatory diseases (IBD, (food) allergy, asthma and COPD) and psychiatric disorders (autism, depression, Parkinson’s disease). The recently awarded grant of Utrecht University, Focus en Massa program Drug Innovation, creates challenging opportunities to in depth study the role of neuro-immune interactions as well as the gut brain-axis in, food allergy, autism and Parkinson’s disease that will further enhance our knowledge of the interaction of innate and adaptive immunity and neurons in chronic inflammatory conditions in the gut and CNS. The neuro-immunopharmacology research group headed by the Prof Dr Aletta Kraneveld within UU is well established, where a strong collaboration with several industries is part of. The research line is part of a (inter)national neuro-immune platform where academia and industry meet. The focus has move forward to neurodevelopmental disorders (autism, preterm birth associated neurodevelopmental disorders), psychiatric disorders (depression) and neurodegenerative diseases (Parkinson’s disease and Alzheimer’s Disease) and research on the gut-immune-brain axis as target for medicine and medical food concepts

Role in the Project

The Division of Pharmacology will lead WP5 (pre-clinical trials in murine models for ASD) where the microbiota as psychotropic and gender bias will be studied. UU will support WP1 (mechanistic pathway hypothesis), WP4 (multi-omics analysis), WP7 (dissemination) and WP8 (exploitation).

Tampere University (UTA)

The organization

The profile of UTA accentuates the university’s multifaceted research and education on society and health. Some 15,200 students are currently pursuing degrees at the UTA. Every year approximately one thousand master's degrees and one hundred doctoral degrees are produced. The personnel number is about 2,200. UTA consists of six faculties, Including Faculty of Medicine and Life Sciences (MED). Together with Tampere University of Technology MED hosts BioMediTech Institute (BMT) that brings together a powerful mix of multidisciplinary expertise in engineering, life sciences and medical technology. Research activities of this project will be implemented within BMT, where over 250 scientists conduct research and education in the fields of cell and molecular biology, genetics, biomaterials, biosensors, computational systems, biotechnology, biomedical engineering, and regenerative medicine. The institute aims not only to integrate and strengthen the local tradition of excellence in basic life-science research and teaching, but also to create new platforms for discovery and innovation. The MED runs an undergraduate program in biotechnology and an international masters program in bioinformatics. In addition, MED organizes a doctoral programme in biomedicine. UTA has been involved in the European framework programme projects since FP5 in 1996. It maintains a research services team to support participation and project management also in the European projects. UTA was awarded the HR Excellence in Research acknowledgement by the European Commission in March 2015

Role in the Project

UTA will lead WP4 (multiomic analysis) and act as a data analysis partner whose responsibilities include to design the experiments, decide number of samples (patients, animals) in the experiments. In the project, the various omics measurements will be performed with the Next Generation Sequencing methods, and UTA’s role is to assist in the data analysis of the resulting data. The main role of our group is to perform the multi- omics data analysis to reveal the dependencies between the various omics measurements and other available information of the samples. UTA will support WP1 (mechanistic pathway hypothesis), WP2 (microbiome, genome and epigenome profiling), WP7 (dissemination) and WP8 (exploitation).

Imperial College of Science, Technology and Medicine (ICL) Department of Biomolecular Medicine

The organization

Imperial College London (ICL) is a science-based institution with an international reputation for excellence in teaching and research (ranked overall 3rd in Europe and 5th in World) that attracts 13,000 students and 6,000 staff of the highest calibre. ICL has the largest medical school in Europe. ICL fosters interdisciplinary research between the basic sciences and medicine to provide real world solutions to individual and public health problems. The Division of Computational and Systems Medicine (headed by Prof Holmes) in the Department of Surgery and Cancer (headed by Prof Nicholson) has one of the world’s largest research teams in metabolic science, with outstanding NMR spectroscopy and MS analytical facilities, providing a unique and ideal environment for development of analytical technology.

Role in the Project

ICL will lead WP3 (metabolome) where it will be responsible for carrying out the metabolic profiling and for modelling and integration of the data. ICL will have a large role in WP7 (dissemination) where it will carry training in outreach activities in Europe and organiye the Global Multiomic Summit. ICL will also support WP1 (mechanistic pathway hypothesis) and WP8 (exploitation).

Johns Hopkins University (JHU) - Department of Mental Health

The organization

Johns Hopkins University is America's first research university and is a world leader in research and education in medicine, public health, the arts, sciences, and engineering. The Johns Hopkins Bloomberg School of Public Health (JHBSPH), which will be the primary school within Johns Hopkins contributing to this project, is the first institution of its kind worldwide and is the largest school of public health in the world. JHBSPH is consistently the top-ranked Public Health School in the United States. Departments within the JHBSPH include: Biochemistry and Molecular Biology; Biostatistics, Environmental Health Sciences; Epidemiology; Health, Behavior and Society; Health Policy and Management; International Health; Mental Health; Molecular Microbiology and Immunology; and Population, Family and Reproductive Health. The Departments and School fully support the PIs and co-investigators through faculty appointments, space, computing resources, and administrative support, including pre-award grant preparation and post-award grant management. The Johns Hopkins Hospital and School of Medicine (JHUSOM) is across the street and the faculty attends seminars in the JHBSPH, JHUSOM, and JHU Hospital regularly. There is no doubt that the scientific environment provided by Johns Hopkins is phenomenal and will greatly aid in the success of this project

Role in the Project

JHU will be a large contributor to WP2 where it will perform all epigenomic measurements, implement existing epigenomic data preprocessing and quality control pipelines, and contribute to the analysis and integration of epigenomic data with the other omics data. In addition, JHU will provide expertise in autism and genetic and epigenetic epidemiology and will collaborate to interpret results in WP4 (multi-omic analysis) and contribute to drafting manuscripts to report findings from this study. JHU will also support WP1 (mechanistic pathway hypotheses), WP7 (dissemination) and WP8 (exploitation), in particular the integration of the study data with other large-scale omic repositories such as the NIH Roadmap Epigenetics database where JHU has gathered experience in a previous ASD related study.